{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+1000+mg",
    "query": {
      "intervention": "Metformin 1000 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 146,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+1000+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T19:13:14.629Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02500147",
      "title": "Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Non-Alcoholic Fatty Liver Disease",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 25 Years · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2011-09-08",
      "completion_date": "2021-03-03",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500147"
    },
    {
      "nct_id": "NCT01763346",
      "title": "Beta Cell Restoration Through Fat Mitigation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prediabetes",
        "Type 2 Diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "gastric banding",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 88,
      "start_date": "2013-06",
      "completion_date": "2018-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763346"
    },
    {
      "nct_id": "NCT02960659",
      "title": "Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Years to 25 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-09",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960659"
    },
    {
      "nct_id": "NCT01555164",
      "title": "A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match metformin",
          "type": "DRUG"
        },
        {
          "name": "Diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 442,
      "start_date": "2012-06",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-09-23",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 60,
      "location_summary": "Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01555164"
    },
    {
      "nct_id": "NCT01541215",
      "title": "Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 135,
      "start_date": "2012-11-13",
      "completion_date": "2020-05-20",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 71,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01541215"
    },
    {
      "nct_id": "NCT02014740",
      "title": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-03",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-06",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014740"
    },
    {
      "nct_id": "NCT02087826",
      "title": "Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Genetics",
        "Metabolism",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Mixed Meal Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 1017,
      "start_date": "2014-04",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02087826"
    },
    {
      "nct_id": "NCT05900284",
      "title": "Safety and Feasibility of Metformin for Sepsis Induced AKI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sepsis",
        "Septic Shock",
        "Acute Kidney Injury",
        "Metformin"
      ],
      "interventions": [
        {
          "name": "Metformin low dose",
          "type": "DRUG"
        },
        {
          "name": "Metformin high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hernando Gomez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-11-08",
      "completion_date": "2026-05-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05900284"
    },
    {
      "nct_id": "NCT00374907",
      "title": "A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin (blinded)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 156,
      "start_date": "2006-09",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2015-05-07",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00374907"
    },
    {
      "nct_id": "NCT03169959",
      "title": "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "2.5 mg Saxagliptin tablet",
          "type": "DRUG"
        },
        {
          "name": "5 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        },
        {
          "name": "5 mg saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "10 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 85,
      "start_date": "2017-05-29",
      "completion_date": "2017-08-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-09-18T19:13:14.629Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03169959"
    }
  ]
}